Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

SPRO holding history

Spero Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

SPRO overviewAll 13F holders of SPROFull Q2 2026 holdings

Shares (Q2 2026)
139,680
Value
$308.7K
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of SPRO by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026139,680$308.7K<0.1%+136,671+4,542.1%AddedHolders
Q1 20263,009$7.04K<0.1%−113,438−97.4%ReducedHolders
Q4 2025116,447$271.3K<0.1%+89,346+329.7%AddedHolders
Q3 202527,101$51.0K<0.1%+18,907+230.7%AddedHolders
Q2 20258,194$23.8K<0.1%+5,368+190.0%AddedHolders
Q1 20252,826$2.04K<0.1%+2,685+1,904.3%AddedHolders
Q4 2024141$145<0.1%−17,388−99.2%ReducedHolders
Q3 202417,529$23.5K<0.1%+17,198+5,195.8%AddedHolders
Q2 2024331$430<0.1%−5,397−94.2%ReducedHolders
Q1 20245,728$9.85K<0.1%+5,399+1,641.0%AddedHolders
Q4 2023329$484<0.1%−26,806−98.8%ReducedHolders
Q3 202327,135$32.8K<0.1%+64+0.2%AddedHolders
Q2 202327,071$39.3K<0.1%−14,452−34.8%ReducedHolders
Q1 202341,523$60.2K<0.1%−4,159−9.1%ReducedHolders
Q4 202245,682$79.0K<0.1%+22,774+99.4%AddedHolders
Q3 202222,908$46.0K<0.1%+22,153+2,934.2%AddedHolders
Q2 2022755$1.00K<0.1%00.0%UnchangedHolders
Q1 2022755$7.00K<0.1%−32,327−97.7%ReducedHolders
Q4 202133,082$529.0K<0.1%+4,260+14.8%AddedHolders
Q3 202128,822$530.0K<0.1%+26,929+1,422.6%AddedHolders
Q2 20211,893$27.0K<0.1%−29,134−93.9%ReducedHolders
Q1 202131,027$456.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.